RESUMEN
The enzyme acetylcholinesterase has a well-established function in limiting the duration of acetylcholine's action at cholinergic synapses. Until recently, the function of this enzyme in non-cholinergic tissues has been a mystery. Recent evidence suggests that some forms of acetylcholinesterase act as proteases to regulate cell growth and development.
Asunto(s)
Acetilcolinesterasa/fisiología , Péptido Hidrolasas , Acetilcolinesterasa/metabolismo , Secuencia de Aminoácidos , Animales , Diferenciación Celular , Humanos , Datos de Secuencia MolecularRESUMEN
The identification of a biochemical marker of Alzheimer's disease (AD) is a major research aim of many groups. Abnormal levels of tau and Abeta have been identified in the cerebrospinal fluid (CSF) of AD patients, although the sensitivity and specificity of the changes in these two biomarkers alone is not sufficient to be of diagnostic value. Recently, our group has identified an abnormality in the glycosylation of acetylcholinesterase (AChE). The increase in this glycoform of AChE is very specific for Alzheimer's disease and is not seen in many other neurological diseases including other dementias.
Asunto(s)
Acetilcolinesterasa/líquido cefalorraquídeo , Enfermedad de Alzheimer/fisiopatología , Biomarcadores/análisis , Acetilcolinesterasa/metabolismo , Glicosilación , Humanos , Sensibilidad y EspecificidadRESUMEN
Proteolytic cleavage of the amyloid protein from the amyloid protein precursor (APP) by APP secretases is a key event in Alzheimer's disease (AD) pathogenesis. alpha-Secretases cleave APP within the amyloid sequences, whereas beta- and gamma-secretases cleave on the N- and C-terminal ends respectively. The transmembrane aspartyl protease BACE has been identified as beta-secretase and several proteases (ADAM-10, TACE, PC7) may be alpha-secretases. A number of studies have suggested that presenilins could be gamma-secretases, although this remains to be demonstrated conclusively. Inhibition of beta- and gamma-secretase, or stimulation of alpha-secretase, is a rational strategy for therapeutic intervention in AD.
Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Ácido Aspártico Endopeptidasas/metabolismo , Endopeptidasas/metabolismo , Secuencia de Aminoácidos , Secretasas de la Proteína Precursora del Amiloide , Precursor de Proteína beta-Amiloide/genética , Animales , Humanos , Datos de Secuencia MolecularRESUMEN
The ability of the 72 kDa gelatinase A to cleave the amyloid protein precursor (APP) was investigated. HeLa cells were transfected with an APP695 plasmid. The cells were incubated with gelatinase A, which cleaved the 110 kDa cell-surface APP, releasing a 100 kDa form of the protein. A peptide homologous to the beta-secretase site was cleaved by gelatinase A adjacent to a glutamate residue at position -3 (beta A4 numbering system). A peptide homologous to the alpha-secretase site was not cleaved. The results demonstrate that 72 kDa gelatinase A is not an alpha-secretase, but that it may have a beta-secretase activity.
Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Endopeptidasas/metabolismo , Proteínas de la Matriz Extracelular , Gelatinasas/metabolismo , Metaloendopeptidasas/metabolismo , Agrecanos , Enfermedad de Alzheimer/metabolismo , Secuencia de Aminoácidos , Secretasas de la Proteína Precursora del Amiloide , Precursor de Proteína beta-Amiloide/genética , Ácido Aspártico Endopeptidasas , Sitios de Unión , Células HeLa , Humanos , Lectinas Tipo C , Metaloproteinasa 2 de la Matriz , Datos de Secuencia Molecular , Proteoglicanos/metabolismo , Relación Estructura-Actividad , Especificidad por SustratoRESUMEN
Deletion mutagenesis studies have suggested that there are two domains within APP which bind heparan sulphate. These domains have been cloned and expressed in the yeast Pichia pastoris. Both recombinant proteins bound to heparin. One domain (APP316-447) was further characterised by binding studies with peptides encompassing this region. Peptides homologous to APP316-346 and APP416-447 were found to bind heparin. Circular dichroism studies show that APP416-447 shifted towards an alpha-helical conformation in the presence of heparin. This study suggests that heparin-binding domains may lie within regions high in alpha-helical structure.
Asunto(s)
Precursor de Proteína beta-Amiloide/genética , Heparina/metabolismo , Estructura Secundaria de Proteína , Enfermedad de Alzheimer , Precursor de Proteína beta-Amiloide/química , Sitios de Unión , Western Blotting , Cromatografía de Afinidad , Dicroismo Circular , Clonación Molecular , Escherichia coli/genética , Expresión Génica , Humanos , Mutagénesis , Fragmentos de Péptidos/química , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/metabolismo , Unión Proteica , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Eliminación de SecuenciaRESUMEN
The amyloid protein precursor (APP) of Alzheimer's disease can stimulate neurite outgrowth in vitro. The receptor responsible for this effect has not been identified. Kunitz protease inhibitor (KPI)-containing forms of APP bind to the low-density lipoprotein receptor-related protein (LRP). As LRP may regulate neurite outgrowth, we examined whether the effects of APP are mediated by LRP. Inhibitors of LRP decreased neurite outgrowth from chick sympathetic neurons. Most LRP ligands (alpha2-macroglobulin, lactoferrin, and lipoprotein lipase) stimulated outgrowth. However, in soluble form, the KPI-containing APP751 was a weak inhibitor of outgrowth. In substrate-bound form, both APP751 and APP695 (which does not bind to LRP) stimulated outgrowth. Thus the effect of substrate-bound APP on neurite outgrowth is not mediated by LRP.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Neuronas/citología , Receptores Inmunológicos/metabolismo , Receptores de LDL/metabolismo , Sistema Nervioso Simpático/citología , Secuencia de Aminoácidos , Precursor de Proteína beta-Amiloide/farmacología , Animales , División Celular , Células Cultivadas , Pollos , Humanos , Ligandos , Proteína 1 Relacionada con Receptor de Lipoproteína de Baja Densidad , Datos de Secuencia Molecular , Neuritas , Neuronas/metabolismo , Sistema Nervioso Simpático/metabolismoRESUMEN
The human amyloid precursor-like protein 2 (APLP2) is a member of the Alzheimer's disease amyloid precursor protein (APP) gene family. The human APLP2 ectodomain (sAPLP2) was expressed in the yeast Pichia pastoris and the recombinant sAPLP2 was purified from the culture medium in a single step by metal-chelating Sepharose chromatography. The neuritotrophic activity of APLP2 was compared to the APP isoforms sAPP695 and sAPP751 on chick sympathetic neurones. APLP2 had neurite outgrowth-promoting activity similar to that of the APP isoforms. This suggests that APP and APLP2 have a similar or related role and supports the idea of a redundancy in function between the APP-gene family proteins.
Asunto(s)
Precursor de Proteína beta-Amiloide/farmacología , Proteínas del Tejido Nervioso/farmacología , Neuritas/efectos de los fármacos , Precursor de Proteína beta-Amiloide/genética , Precursor de Proteína beta-Amiloide/fisiología , Animales , Secuencia de Bases , Pollos , Cartilla de ADN/genética , Ganglios Simpáticos/efectos de los fármacos , Ganglios Simpáticos/crecimiento & desarrollo , Expresión Génica , Humanos , Técnicas In Vitro , Ratones , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/fisiología , Pichia/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/farmacologíaRESUMEN
The major soluble protein of bovine chromaffin granules chromogranin A was purified by reverse-phase high performance liquid chromatography. Brief incubations with either acetylcholinesterase or trypsin cleaved chromogranin A to yield two chromogranin-immunoreactive polypeptides which were similar in molecular weight to two of the major endogenous chromogranin polypeptides. A number of peptidase inhibitors which strongly inhibited tryptic digestion of chromogranin A also inhibited the acetylcholinesterase digestion, although they were less potent. More prolonged digestion of chromogranin A with acetylcholinesterase produced a large number of peptides which were similar to some of the endogenous chromogranin peptides in their elution profile by high performance liquid chromatography. In contrast, complete tryptic digestion of chromogranin A yielded peptides with a totally different elution profile. The experiments indicate that acetylcholinesterase possesses a peptidase activity which is similar, but not identical to trypsin, and suggest that a second non-tryptic activity is also present. They also suggest that acetylcholinesterase, an enzyme found in chromaffin cells, may process chromogranin A to yield lower molecular weight chromogranins in bovine chromaffin cells.
Asunto(s)
Acetilcolinesterasa/metabolismo , Cromograninas/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Procesamiento Proteico-Postraduccional , Animales , Bovinos , Cromatografía Líquida de Alta Presión , Cromogranina A , Electroforesis en Gel de Poliacrilamida , Hidrólisis , Técnicas para Inmunoenzimas , Peso Molecular , Péptidos/análisis , Péptidos/metabolismo , Tripsina/metabolismo , Inhibidores de TripsinaRESUMEN
Acetylcholinesterase (EC 3.1.1.7) has been shown to possess an intrinsic peptidase activity. [Chubb et al. (1983), Neuroscience 10, 1369-1383]. To examine this activity further, the breakdown of a model hexapeptide (leu-trp-met-arg-phe-ala) LWMRFA was studied. Affinity-purified eel acetylcholinesterase rapidly cleaved the hexapeptide in a trypsin-like manner to produce two peptides (LWMR and FA). Acetylcholinesterase more slowly cleaved the C-terminal alanine residue from the peptide to yield LWMRF. Although the enzyme showed preference for cleaving the hexapeptide at its C-terminal, it was also able to cleave the N-terminal leucine residue form the tryptic product LWMR. Hydrolysis of the peptide at the tryptic site (arg4-phe5) was strongly inhibited by the trypsin inhibitor diisopropylfluorophosphate. Cleavage of the C-terminal alanine was only poorly inhibited by diisopropylfluorophosphate, but more strongly inhibited by metal-ion chelating agents, and it was increased in the presence of Zn2+ and Co2+. The pH optimum for cleavage at the tryptic site was 6, while that for the carboxypeptidase site was 8-9. These results show that acetylcholinesterase can hydrolyse peptides like a trypsin-like endopeptidase and a Zn2+- or Co2+-dependent exopeptidase, and they suggest that these two peptidase activities are associated with two separate active sites on the acetylcholinesterase molecule. As both peptidase activities eluted with acetylcholinesterase from a TSK 4000SW column when it was chromatographed by high-performance liquid chromatography, it is unlikely that the presence of either peptidase activity could be attributable to a contaminant in the acetylcholinesterase preparation. We suggest that acetylcholinesterase may be involved in the breakdown of bioactive peptides or their precursors in neuroendocrine cells.
Asunto(s)
Acetilcolinesterasa , Péptido Hidrolasas , Catálisis , Cationes Bivalentes/farmacología , Inhibidores de la Colinesterasa , Cromatografía Líquida de Alta Presión , Concentración de Iones de Hidrógeno , Hidrólisis , Fragmentos de Péptidos/análisis , Péptidos , Inhibidores de Proteasas/farmacologíaRESUMEN
The epsilon4 allele of apolipoprotein E gene is a major risk factor for Alzheimer's disease. However, the mechanism by which the E4 isoform of apolipoprotein E increases the risk of Alzheimer's disease is poorly understood. To determine whether the isoform-specific effects of apolipoprotein E may be mediated via clearance of bound beta-amyloid, we examined the uptake of beta-amyloid 1-40 into Chinese hamster ovary cells in the presence or absence of the apolipoprotein E isoforms E2, E3 and E4. Apolipoprotein E2 and E3 treatments were associated with higher association of beta-amyloid with cells as compared to treatment with E4. Heparin blocked the association of beta-amyloid with cells, as did an antibody to one of the apolipoprotein E receptors (the low-density lipoprotein receptor-related protein). Thus, the apolipoproteins E2 and E3, but not E4, may play important roles in the clearance of beta-amyloid from the extracellular space via the low-density lipoprotein receptor-related protein.
Asunto(s)
Péptidos beta-Amiloides/metabolismo , Apolipoproteínas E/farmacología , Células CHO/metabolismo , Fragmentos de Péptidos/metabolismo , Péptidos beta-Amiloides/antagonistas & inhibidores , Péptidos beta-Amiloides/farmacocinética , Animales , Anticuerpos/farmacología , Apolipoproteína E2 , Apolipoproteína E3 , Apolipoproteína E4 , Cricetinae , Heparina/farmacología , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/farmacocinética , Receptores de LDL/inmunologíaRESUMEN
Many studies have shown that breakdown of the amyloid protein precursor (APP) to produce the amyloid protein is an important step in the pathogenic mechanism which causes Alzheimer's disease (AD). However, little is known about the normal function of APP. Developmental studies show that APP expression increases during the period of brain development when neurite outgrowth and synaptogenesis is maximal. APP is expressed highly within growing neurites and in growth cones, and purified APP has been shown to stimulate neurite outgrowth from cells in culture. Thus APP may regulate neurite outgrowth or synaptogenesis in vivo. APP is actively secreted from many cells, and the C-terminally secreted APP has been shown to associate with components of the extracellular matrix, such as the heparan sulphate proteoglycans (HSPGs). Two putative heparin-binding domains on APP have been reported. Binding of HSPGs to an N-terminal heparin-binding domain (HBD-1) stimulates the effect of substrate-bound APP on neurite outgrowth. In the mature nervous system, APP may play an important role in the regulation of wound repair. It is highly likely that studies on the normal functions of APP will shed further light on aspects of the pathogenesis of AD.
RESUMEN
Chromogranin A (CGA) is a member of a family of highly acidic proteins co-stored and co-secreted with adrenaline and noradrenaline in the adrenal medulla. A number of biologically active fragments of CGA (CGAFs) have been characterized including a group of small N-terminal fragments collectively named vasostatins due to their vascular inhibitory activity. In the present study, the release of CGAFs, including CGA N-terminal fragments, from the isolated, retrogradely perfused bovine adrenal gland, has been studied under basal conditions and during nerve stimulation and perfusion with acetylcholine. The CGAFs were characterized by SDS-PAGE followed by immunoblotting with antisera to specific sequences within the CGA molecule. Many different CGAFs were released during stimulation of the glands. Antisera to CGA1-40 and CGA44-76 detected a 7 kD protein whose release was increased during stimulation. This component co-migrated with synthetic CGA1-76, was not immunoreactive to antisera to CGA79-113 or CGA124-143, and was seen whether or not the serine protease inhibitor aprotinin was present in the perfusion medium. The release of an approximately 18 kD component, which stained with antisera to CGA1-40, CGA44-76 and CGA79-113, but not to chromostatin (CGA124-143), was also increased during stimulation. Components of 22 kD and larger were detected with antisera to chromostatin, but not with antisera to CGA1-40, CGA44-76 and CGA79-113. Two of these components of 22 to 24 kD were enhanced during nerve stimulation in the presence of aprotinin. The results indicate that processed chromogranin A fragments are secreted from the bovine adrenal medulla during stimulation of chromaffin cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Glándulas Suprarrenales/metabolismo , Cromograninas/metabolismo , Acetilcolina/farmacología , Glándulas Suprarrenales/efectos de los fármacos , Glándulas Suprarrenales/inervación , Médula Suprarrenal/química , Animales , Aprotinina/farmacología , Western Blotting , Bovinos , Gránulos Cromafines/química , Cromogranina A , Cromograninas/aislamiento & purificación , Estimulación Eléctrica , Electroforesis en Gel de Poliacrilamida , Immunoblotting , Técnicas In Vitro , Fragmentos de Péptidos/metabolismo , PerfusiónRESUMEN
The cholinesterases are members of the serine hydrolase family, which utilize a serine residue at the active site. Acetylcholinesterase (AChE) is distinguished from butyrylcholinesterase (BChE) by its greater specificity for hydrolysing acetylcholine. The function of AChE at cholinergic synapses is to terminate cholinergic neurotransmission. However, AChE is expressed in tissues that are not directly innervated by cholinergic nerves. AChE and BChE are found in several types of haematopoietic cells. Transient expression of AChE in the brain during embryogenesis suggests that AChE may function in the regulation of neurite outgrowth. Overexpression of cholinesterases has also been correlated with tumorigenesis and abnormal megakaryocytopoiesis. Acetylcholine has been shown to influence cell proliferation and neurite outgrowth through nicotinic and muscarinic receptor-mediated mechanisms and thus, that the expression of AChE and BChE at non-synaptic sites may be associated with a cholinergic function. However, structural homologies between cholinesterases and adhesion proteins indicate that cholinesterases could also function as cell-cell or cell-substrate adhesion molecules. Abnormal expression of AChE and BChE has been detected around the amyloid plaques and neurofibrillary tangles in the brains of patients with Alzheimer's disease. The function of the cholinesterases in these regions of the Alzheimer brain is unknown, but this function is probably unrelated to cholinergic neurotransmission. The presence of abnormal cholinesterase expression in the Alzheimer brain has implications for the pathogenesis of Alzheimer's disease and for therapeutic strategies using cholinesterase inhibitors.
Asunto(s)
Enfermedad de Alzheimer/enzimología , Colinesterasas/fisiología , Neoplasias/enzimología , Secuencia de Aminoácidos , Animales , Diferenciación Celular/fisiología , Colinesterasas/genética , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Pliegue de Proteína , Estructura Secundaria de ProteínaRESUMEN
Alzheimer's disease (AD) is characterized by the presence of extracellular amyloid plaques, which contain a protein referred to as the amyloid or beta A4 protein. The beta A4 protein is derived from a larger precursor protein (APP). Studies of autosomal-dominant forms of AD have established the central role of APP in the pathogenesis of the disease. Despite considerable research, the function of APP is unknown. APP can be processed by at least two separate routes. The first route involves a protease known as "APP secretase," which cleaves within the amyloid sequence, thereby mitigating amyloid formation. The second route may result in the production of potentially amyloidogenic fragments. Our studies suggest that following release from the cell membrane, APP interacts with components of the extracellular matrix (ECM) such as the heparan sulfate proteoglycans (HSPG's). The interaction of APP with HSPG's may be important for the function of APP. Substratum-bound APP was found to dramatically increase neurite outgrowth and survival of chick sympathetic neurons in vitro. This effect was dependent upon the presence of substratum-bound HSPG. The results suggest that normally, when bound to the ECM, APP functions to promote neurite outgrowth and/or cell survival. Loss of this normal trophic function might occur in AD, when APP is proteolytically processed via the amyloidogenic pathway.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/biosíntesis , Precursor de Proteína beta-Amiloide/metabolismo , Encéfalo/metabolismo , Procesamiento Proteico-Postraduccional , Secuencia de Aminoácidos , Animales , Sitios de Unión , Secuencia de Consenso , Matriz Extracelular/metabolismo , Heparina/metabolismo , Humanos , Datos de Secuencia MolecularRESUMEN
The hallmark of Alzheimer's disease (AD) is the deposition of amyloid plaques and neurofibrillary tangles in the brain. The relationship between amyloid deposition and the cognitive deficit is still unclear. The amyloid beta A4 protein is produced by proteolytic cleavage of the amyloid protein precursor (APP). Very little is known about the normal function of APP and the role the protein may play in pathogenesis. Several studies have shown that APP is important for the regulation of neurite outgrowth. Our studies support these findings and indicate that the neurite outgrowth-promoting effects of APP are stimulated by an interaction between APP and specific proteoglycans. Using site-directed mutagenesis, a heparan sulfate binding site which mediates this effect has been mapped to the N-terminus of APP (residues 96-110, HBD-1). A peptide homologous to HBD-1 blocks the trophic effects of APP in cell culture. To purify specific proteoglycans which stimulate the action of APP, an affinity column was constructed using a biotinylated peptide homologous to HBD-1 coupled to streptavidin-agarose. Two proteoglycans were isolated from a crude brain cell conditioned medium by affinity chromatography. The purified proteoglycans bound APP saturably with high affinity and stimulated the action of APP on neurite outgrowth from chick sympathetic neurons. Digestion of the proteoglycan fraction with heparitinase I or chondroitinase ABC demonstrated the presence of two major proteins, a heparan sulfate proteoglycan with a core protein of 63-67 kD molecular mass and a chondroitin sulfate proteoglycan with a core protein of 100-110 kD molecular mass. The results demonstrate that APP binds to at least two proteoglycans and that this interaction may regulate the trophic effects of the protein. The interaction of specific APP-binding proteoglycans with amyloid plaques may disturb the normal function of APP and contribute to the neuritic degeneration that is commonly seen around the amyloid plaque cores.
Asunto(s)
Enfermedad de Alzheimer/etiología , Heparitina Sulfato/fisiología , Proteoglicanos/fisiología , Precursor de Proteína beta-Amiloide/fisiología , Matriz Extracelular/metabolismo , Proteoglicanos de Heparán Sulfato , HumanosRESUMEN
We have identified and characterized the ligand binding properties of the Alzheimer's disease (AD) beta A4 amyloid protein precursor (APP), mapped the APP ligand binding sites and analyzed the regulation of APP expression, biogenesis and metabolism by components of the extracellular matrix (ECM) and cytokines.
Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Citocinas/fisiología , Matriz Extracelular/fisiología , HumanosRESUMEN
Our previous studies have shown that a minor isoform of acetylcholinesterase (AChE) is increased in the cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients. In the present study, the glycosylation of butyrycholinesterase (BuChE) was found to be altered in AD CSF. By combining an analysis of CSF AChE and BuChE glycosylation, it is possible to identify cases of AD with more than 90% sensitivity and specificity.
Asunto(s)
Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/enzimología , Butirilcolinesterasa/líquido cefalorraquídeo , Canales de Calcio Tipo L/metabolismo , Glicosilación , Humanos , Isoenzimas/líquido cefalorraquídeoRESUMEN
A protease activity which co-purified with affinity-purified fetal bovine serum acetylcholinesterase (AChE) has been shown to release the amyloid protein precursor (APP) of Alzheimer's disease from cell membranes. The nature of this protease and its relationship to AChE have not been established. In this study, the protease activity was found to be recovered with a minor dimeric form of AChE. This minor form (AChEII) was distinguished from the more abundant tetrameric form (AChEI) by a higher catalytic subunit relative molecular mass (M(r)) of 80,000 (80K), and by a lower affinity for edrophonium-Sepharose. The difference in subunit M(r) was due to differing degrees of glycosylation, as deglycosylation of both AChEI and AChEII gave rise to a similar subunit M(r) of 62K. The protease activity recovered with AChEII was not an intrinsic property of the esterase, as it was separated from the esterase by anion-exchange chromatography, and by immunoprecipitation with anti-AChE antibodies. AChEI possessed a similar subunit M(r) to the tetrameric form of AChE secreted from the bovine adrenal gland, while AChEII possessed a similar subunit molecular weight to the dimeric membrane-bound form of bovine erythrocyte AChE. Thus, it is possible that AChEII may be a solubilised form of a dimeric glycosylphosphatidyl inositol-linked AChE.
Asunto(s)
Acetilcolinesterasa/aislamiento & purificación , Sangre Fetal/enzimología , Isoenzimas/aislamiento & purificación , Péptido Hidrolasas/aislamiento & purificación , Acetilcolinesterasa/sangre , Acetilcolinesterasa/química , Animales , Bovinos , Glicosilación , Isoenzimas/sangre , Isoenzimas/química , Péptido Hidrolasas/sangre , Conformación ProteicaRESUMEN
Acetylcholinesterase was purified by passage through 3 affinity columns. The enzyme so purified was found to be homogeneous by electrophoresis and the peptidase and AChE activities co-eluted from a high pressure liquid chromatography column. The purified AChE degraded the chromogranins, the soluble proteins from the adrenal chromaffin granules, at a rate of nearly 8 micrograms/microgram AChE/h. The rate was fastest with the largest chromogranins, but proteins across the whole molecular weight spectrum were hydrolyzed. Immunoassay of extracts after incubation with AChE showed that enkephalin-like material had been produced. Incubations were also done with chromogranins that had been fractionated by size exclusion chromatography. The AChE degraded protein in all fractions and generated enkephalin-like immunoreactive material in fractions where it was produced by sequential treatment with trypsin and carboxypeptidase B. It seems likely, therefore, that AChE can hydrolyze some of the enkephalin precursors that are sensitive to trypsin and carboxypeptidase B, but the one-step nature of its action suggests a mode of action with fewer restrictions. It is concluded that AChE can hydrolyze proteins of widely differing sizes and the data add to the evidence that AChE is able to hydrolyze enkephalin precursors resulting in the generation of immunoreactive peptide.
Asunto(s)
Acetilcolinesterasa , Cromograninas , Endopeptidasas , Encefalinas , Proteínas del Tejido Nervioso , Glándulas Suprarrenales/análisis , Animales , Catálisis , Bovinos , Gránulos Cromafines/análisis , Cromograninas/aislamiento & purificación , HidrólisisRESUMEN
Angiotensin IV (Val-Tyr-Ile-His-Pro-Phe) is reported to enhance apomorphine induced stereotypy and to improve memory recall through actions on specific binding sites in the central nervous system. In the present study, 10 nM angiotensin IV or angiotensin II inhibited neurite outgrowth from cultured E11 chicken paravertebral sympathetic neurones by 25%. The effects of both peptides were inhibited by a 1 microM concentration of the angiotensin IV analogues. WSU 4042, Nle1-Y-I-amide or Nle1-AIV, but not by the avian angiotensin II antagonists, [Sar1,Ile8]Ang II or CGP 42112, suggesting that the inhibition of neurite outgrowth by both peptides is mediated by the angiotensin IV binding site. These results suggest that angiotensin IV may be involved in neurite modelling and may therefore have an important role in neuronal development.